Detalhe da pesquisa
1.
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Nature
; 600(7888): 319-323, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819663
2.
Egg envelope formation of medaka Oryzias latipes requires ZP proteins originating from both the liver and ovary.
J Biol Chem
; 299(4): 104600, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906145
3.
Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease.
Clin Exp Pharmacol Physiol
; 49(4): 492-500, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35066915
4.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Int J Clin Oncol
; 27(1): 112-120, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643820
5.
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
Int J Clin Oncol
; 26(3): 515-522, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33184754
6.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol
; 20(5): 625-635, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30975627
7.
Correction to: Osimertinib in poor performance status patients with T790Mpositive advanced nonsmallcell lung cancer after progression of first- and secondgeneration EGFRTKI treatments (NEJ032B).
Int J Clin Oncol
; 27(4): 823-824, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257278
8.
CAMP (C13orf8, ZNF828) is a novel regulator of kinetochore-microtubule attachment.
EMBO J
; 30(1): 130-44, 2011 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-21063390
9.
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Oncologist
; 19(4): 352-3, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24682465
10.
Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
JTO Clin Res Rep
; 5(4): 100655, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38706978
11.
Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.
Bioorg Med Chem Lett
; 23(1): 90-5, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23206862
12.
Speech Perception in Noise and Sound Localization for Cochlear Implant With Single-Sided Deafness Compared With Contralateral Routing of Signal Hearing Aids.
Otol Neurotol
; 44(4): 331-338, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36946362
13.
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.
Cancers (Basel)
; 15(17)2023 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686506
14.
Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.
Anticancer Res
; 43(11): 5031-5040, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37909987
15.
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.
Biomedicines
; 11(9)2023 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37760942
16.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
JTO Clin Res Rep
; 4(12): 100593, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38046378
17.
Identification of a novel and orally available benzimidazole derivative as an NPY Y5 receptor antagonist with in vivo efficacy.
Bioorg Med Chem Lett
; 22(21): 6554-8, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23025998
18.
Design, synthesis and identification of novel benzimidazole derivatives as highly potent NPY Y5 receptor antagonists with attractive in vitro ADME profiles.
Bioorg Med Chem Lett
; 22(17): 5498-502, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22853998
19.
Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist.
Bioorg Med Chem Lett
; 22(5): 2020-3, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22300657
20.
Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).
Med Oncol
; 39(11): 163, 2022 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972704